ViroGates A/S Stock price

Equities

VIRO

DK0061030574

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen 11:49:59 2024-03-27 am EDT 5-day change 1st Jan Change
6.5 DKK +0.62% Intraday chart for ViroGates A/S -13.56% +7.97%
Sales 2022 15.2M 2.2M Sales 2023 6.99M 1.01M Capitalization 38.81M 5.61M
Net income 2022 -9M -1.3M Net income 2023 -12M -1.74M EV / Sales 2022 8.18 x
Net cash position 2022 9.88M 1.43M Net cash position 2023 10.73M 1.55M EV / Sales 2023 4.02 x
P/E ratio 2022
-13.5 x
P/E ratio 2023
-1.72 x
Employees 10
Yield 2022 *
-
Yield 2023
-
Free-Float 72.75%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.62%
1 week-13.56%
Current month-14.25%
1 month-17.09%
3 months+4.17%
6 months-69.05%
Current year+7.97%
More quotes
1 week
5.52
Extreme 5.52
7.00
1 month
5.52
Extreme 5.52
8.16
Current year
5.52
Extreme 5.52
9.14
1 year
4.98
Extreme 4.98
47.10
3 years
4.98
Extreme 4.98
252.00
5 years
4.98
Extreme 4.98
252.00
10 years
4.98
Extreme 4.98
252.00
More quotes
Managers TitleAgeSince
Founder 61 00-12-31
Chief Executive Officer 56 11-03-31
Director of Finance/CFO 33 23-02-28
Members of the board TitleAgeSince
Director/Board Member 57 16-03-31
Chairman 62 22-03-31
Director/Board Member 63 15-01-31
More insiders
Date Price Change Volume
24-03-27 6.5 +0.62% 19,229
24-03-26 6.46 +3.19% 878
24-03-25 6.26 -6.57% 13,196
24-03-22 6.7 -10.90% 10,772
24-03-21 7.52 -0.27% 20,011

Delayed Quote Nasdaq Copenhagen, March 27, 2024 at 11:49 am EDT

More quotes
ViroGates A/S is a Denmark-based medical technology company. Its develops a product line suPARnostic, which measures the amount of amount of soluble urokinase Plasminogen Activator Receptor protein (suPAR) in human blood. The plasma level of suPAR reflects immune activation and is increased in such infectious diseases as HIV-1-infection, malaria, tuberculosis, Streptococcus pneumonia bacteraemia, sepsis, pneumococcal pneumonia and bacterial and viral CNS infection. Also, high suPAR levels are associated with increased inflammation, disease progression and risk of mortality. Thus, measuring suPAR levels serves as a marker to determine chances for survival upon hospital admission, as well as for monitoring for prevention of disease progression and earlier intervention time point. suPARnostic has two versions: Quantitative Point of Care Quick Triage test, which serves for patient triage in acute care, and Quantitative ELISA Assay that aims at clinical routine use.
Calendar
More about the company
  1. Stock
  2. Equities
  3. Stock ViroGates A/S - Nasdaq Copenhagen